Phase III Insulin Add-On Asia Regional Program - ST

Inclusion Criteria: * Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit * Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment Inclusion criteria for randomization: HbA1c ≥ 7.5 and ≤ 10.5% at Day -14 Exclusion Criteria: * Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment * History of diabetic ketoacidosis of hyperosmolar nonketotic coma * Clinically diagnosed Type 1 diabetes mellitus * Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV * Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg * History of unstable or rapidly progressing renal disease * History of severe hepatobiliary disease * Mallingancy within 5 years of the screening/enrollment visit